Insider Selling: Tempus AI (NASDAQ:TEM) CAO Sells $181,392.12 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 4,116 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the transaction, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $46.18 on Friday. The firm has a 50-day simple moving average of $48.89 and a 200-day simple moving average of $59.29. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of -26.85 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.24) earnings per share. On average, equities analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new stake in Tempus AI during the third quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the third quarter worth about $38,000. Tsfg LLC increased its position in shares of Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after acquiring an additional 500 shares during the last quarter. Finally, Cloud Capital Management LLC acquired a new stake in shares of Tempus AI during the third quarter valued at about $44,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. BTIG Research reduced their target price on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, May 8th. HC Wainwright reduced their target price on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Wednesday, March 11th. TD Cowen raised their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Mizuho assumed coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $68.64.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.